Literature DB >> 24065049

[Therapeutic management of non-valvular atrial fibrillation. Update 2013].

K Bode1, P Sommer, A Bollmann, G Hindricks.   

Abstract

In western countries one in ten of elderly persons (> 65 years old) will develop atrial fibrillation. The main goal in atrial fibrillation therapy is the prophylaxis of thromboembolic complications through anticoagulation according to the individual risk profile (CHA2DS2-Vasc score) of patients and treatment of cardiovascular comorbidities. Symptoms during atrial fibrillation guide the further therapeutic concept. Doctors can deploy a rate control strategy with a heart rate at rest less than 110/min and/or a rhythm control strategy with cardioversion, antiarrhythmic drugs and catheter ablation to alleviate complaints. To what extent maintaining the sinus rhythm improves the prognosis of atrial fibrillation patients is part of ongoing trials.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24065049     DOI： 10.1007/s00059-013-3940-x

Source DB:  PubMed          Journal:  Herz        ISSN： 0340-9937            Impact factor:   1.443


  64 in total

1.  Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial.

Authors:  David A Fitzmaurice; F D Richard Hobbs; Sue Jowett; Jonathon Mant; Ellen T Murray; Roger Holder; J P Raftery; S Bryan; Michael Davies; Gregory Y H Lip; T F Allan
Journal:  BMJ       Date:  2007-08-02

2.  A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study.

Authors:  F D R Hobbs; D A Fitzmaurice; J Mant; E Murray; S Jowett; S Bryan; J Raftery; M Davies; G Lip
Journal:  Health Technol Assess       Date:  2005-10       Impact factor: 4.014

3.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association.

Authors:  A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof
Journal:  Europace       Date:  2012-08-24       Impact factor: 5.214

4.  Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society.

Authors:  Paulus Kirchhof; Anne B Curtis; Allan C Skanes; Anne M Gillis; L Samuel Wann; A John Camm
Journal:  Eur Heart J       Date:  2013-01-25       Impact factor: 29.983

5.  Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion.

Authors:  Rangadham Nagarakanti; Michael D Ezekowitz; Jonas Oldgren; Sean Yang; Michael Chernick; Timothy H Aikens; Greg Flaker; Josep Brugada; Gabriel Kamensky; Amit Parekh; Paul A Reilly; Salim Yusuf; Stuart J Connolly
Journal:  Circulation       Date:  2011-01-03       Impact factor: 29.690

6.  Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range.

Authors:  Stuart J Connolly; Janice Pogue; John Eikelboom; Gregory Flaker; Patrick Commerford; Maria Grazia Franzosi; Jeffrey S Healey; Salim Yusuf
Journal:  Circulation       Date:  2008-10-27       Impact factor: 29.690

7.  Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy.

Authors:  Ayman A Hussein; David O Martin; Walid Saliba; Deven Patel; Saima Karim; Omar Batal; Mustafa Banna; Michelle Williams-Andrews; Minerva Sherman; Mohamed Kanj; Mandeep Bhargava; Thomas Dresing; Thomas Callahan; Patrick Tchou; Luigi Di Biase; Salwa Beheiry; Bruce Lindsay; Andrea Natale; Oussama Wazni
Journal:  Heart Rhythm       Date:  2009-07-10       Impact factor: 6.343

8.  Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study.

Authors:  Thomas J Wang; Martin G Larson; Daniel Levy; Ramachandran S Vasan; Eric P Leip; Philip A Wolf; Ralph B D'Agostino; Joanne M Murabito; William B Kannel; Emelia J Benjamin
Journal:  Circulation       Date:  2003-05-27       Impact factor: 29.690

9.  A randomized assessment of the incremental role of ablation of complex fractionated atrial electrograms after antral pulmonary vein isolation for long-lasting persistent atrial fibrillation.

Authors:  Hakan Oral; Aman Chugh; Kentaro Yoshida; Jean F Sarrazin; Michael Kuhne; Thomas Crawford; Nagib Chalfoun; Darryl Wells; Warangkna Boonyapisit; Srikar Veerareddy; Sreedhar Billakanty; Wai S Wong; Eric Good; Krit Jongnarangsin; Frank Pelosi; Frank Bogun; Fred Morady
Journal:  J Am Coll Cardiol       Date:  2009-03-03       Impact factor: 24.094

10.  Atrial fibrillation: its prevalence and risk factor profile in the German general population.

Authors:  Renate B Schnabel; Sandra Wilde; Philipp S Wild; Thomas Munzel; Stefan Blankenberg
Journal:  Dtsch Arztebl Int       Date:  2012-04-20       Impact factor: 5.594
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.